Study S002116

Treatment With Liraglutide as add-on to Insulin in Type 1 Diabetic Patients. Effects on Glycemic Control and Counterregulation and Cognitive Performance During Hypoglycaemia

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02092896
Acronym: T1DMLIRA
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 40
Start: 2013-03
Primary completion: 2014-10
Lead sponsor: Hvidovre University Hospital
Conditions: Diabetes; Diabetes Mellitus, Type 1
Interventions: DRUG:Liraglutide; DRUG:Placebo
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2012-002526-67

Registered primary outcomes

Change from baseline in HbA1c (glycosylated haemoglobin) [Week 0, week 12]
Changes from baseline in EEG and cognitive performances [week 0, week 12]
Change from baseline in gastric emptying rate [week 0, week 12]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0026080	Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study. Frandsen CS, Diabetes care	2015	Randomized trial	PMID 26486191 DOI	cites ClinicalTrials.gov:NCT02092896; registry reference DERIVED:26486191